Treatment of a new coronavirus infection (COVID-19).Areplivir
- For the treatment of internal organs: antiviral agent for the whole body
- Appointment: Treatment of a new coronavirus infection (COVID-19).
- Side effect:
From the blood and lymphatic system: often - neutropenia, leukopenia; rarely - leukocytosis, monocytosis, reticulocytopenia.
From the side of metabolism: often - hyperuricemia, hypertriglyceridemia; infrequently - glucosuria; rarely - hypokalemia.
From the immune system: infrequently - rash; rarely - eczema, itching.
From the respiratory system: rarely - bronchial asthma, sore throat, rhinitis, nasopharyngitis.
From the digestive system: often - diarrhea; infrequently - nausea, vomiting, abdominal pain; rarely - abdominal discomfort, duodenal ulcer, bloody stools, gastritis.
From the liver and biliary tract: often - increased activity of ALT, AST, GGT; rarely - increased activity of alkaline phosphatase, increased concentration of bilirubin in the blood.
Other: rarely - abnormal behavior, increased activity of CPK, hematuria, laryngeal polyp, hyperpigmentation, impaired taste sensitivity, hematoma, blurred vision, eye pain, vertigo, supraventricular extrasystoles, chest pain.
- Contraindications: Hypersensitivity to favipiravir; severe liver failure (class C according to the child - Pugh classification); severe renal failure and end-stage renal failure (GFR<30 ml/min); pregnancy, pregnancy planning, breastfeeding; children under 18 years of age.
Patients with a history of gout and hyperuricemia (possible increase in uric acid levels and exacerbation of symptoms), elderly patients, patients with moderate hepatic insufficiency (GFR<60 ml/min and ≥30 ml/min).